Biomarkers /
ERBB2 Loss
Back to Biomarkers List
Overview
ERBB2 Loss is present in 0.05% of AACR GENIE cases, with high grade ovarian serous adenocarcinoma, invasive breast carcinoma, anal squamous cell carcinoma, breast invasive ductal carcinoma, and conventional glioblastoma multiforme having the greatest prevalence [4].
Biomarker-Directed Therapies
ERBB2 Loss is a predictive biomarker for use of fulvestrant, everolimus, abemaciclib, aromatase inhibitor, alpelisib, exemestane, letrozole, palbociclib, ribociclib, anastrozole, atezolizumab, nab-paclitaxel, pembrolizumab, sacituzumab govitecan, and tamoxifen in patients.
Of the therapies with ERBB2 Loss as a predictive biomarker, 12 are FDA-approved and 14 have NCCN guidelines in at least one clinical setting.
Breast carcinoma has the most therapies targeted against ERBB2 Loss or its related pathways [5].
Abemaciclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. |
Everolimus +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (BNF) |
Letrozole +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Neoadjuvant (BNF) |
Pembrolizumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA) | |
| Note: Indicated in combination with chemotherapy for patients with locally recurrent, unresectable, or metastatic TNBC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥10]. |
Sacituzumab Govitecan +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. |
Abemaciclib + Aromatase Inhibitor +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated as initial endocrine-based therapy for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer. |
Abemaciclib + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. |
Alpelisib + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: PIK3CA E545Q, PIK3CA Q546K, PIK3CA Q546P, PIK3CA E365K, PIK3CA E453K, PIK3CA G1049R, PIK3CA G106V, PIK3CA G118D, PIK3CA K111E, PIK3CA K111N, PIK3CA M1043I, PIK3CA M1043V, PIK3CA N345K, PIK3CA P447_L455del, PIK3CA P539R, PIK3CA R108H, PIK3CA R88Q, PIK3CA R93W, PIK3CA T1025A, PIK3CA V344G, PIK3CA V344M Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative, PIK3CA-mutated, recurrent or metastatic breast cancer. |
Anastrozole + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastatic breast cancer as first line therapy. |
Aromatase Inhibitor + Palbociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: FDA approved for HR-positive, HER2-negative advanced or metastatic breast cancer as initial endocrine-based therapy in postmenopausal women or in men. |
Aromatase Inhibitor + Ribociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for pre/perimenopausal or postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. |
Atezolizumab + Nab-Paclitaxel +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] of any intensity covering ≥ 1% of the tumor area. |
Everolimus + Exemestane +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for postmenopausal women with advanced HR+, HER2- breast cancer after failure of treatment with letrozole or anastrozole. |
Everolimus + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastastic breast cancer as subsequent line therapy. |
Everolimus + Tamoxifen +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastatic breast cancer as subsequent line therapy. |
Fulvestrant + Letrozole +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastastic breast cancer as first line therapy. |
Fulvestrant + Palbociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. |
Fulvestrant + Ribociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy, or following disease progression on endocrine therapy. |
Clinical Trials
ERBB2 Loss serves as an inclusion eligibility criterion in 958 clinical trials, of which 718 are open and 240 are closed. Of the trials that contain ERBB2 Loss as an inclusion criterion, 20 are early phase 1 (15 open), 267 are phase 1 (181 open), 148 are phase 1/phase 2 (110 open), 373 are phase 2 (287 open), 12 are phase 2/phase 3 (11 open), 100 are phase 3 (86 open), 6 are phase 4 (2 open), and 32 are no phase specified (26 open).
Trials with ERBB2 Loss in the inclusion eligibility criteria most commonly target breast carcinoma, invasive breast carcinoma, breast adenocarcinoma, gastric adenocarcinoma, and adenocarcinoma of the gastroesophageal junction [5].
Paclitaxel, pembrolizumab, fulvestrant, cyclophosphamide, and palbociclib are the most frequent therapies in trials with ERBB2 Loss as an inclusion criteria [5].
Significance of ERBB2 Loss in Diseases
Breast Carcinoma +
ERBB2 is altered in 13.78% of breast carcinoma patients with ERBB2 Loss present in 0.03% of all breast carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 820 clinical trials for breast carcinoma, of which 594 are open and 226 are closed. Of the trials that contain ERBB2 Loss and breast carcinoma as inclusion criteria, 17 are early phase 1 (12 open), 243 are phase 1 (159 open), 137 are phase 1/phase 2 (102 open), 308 are phase 2 (226 open), 9 are phase 2/phase 3 (8 open), 77 are phase 3 (66 open), 6 are phase 4 (2 open), and 23 are no phase specified (19 open) [5].
Everolimus, exemestane, alpelisib, fulvestrant, pembrolizumab, letrozole, ribociclib, palbociclib, tamoxifen, abemaciclib, aromatase inhibitor, atezolizumab, nab-paclitaxel, anastrozole, and sacituzumab govitecan have evidence of efficacy in patients with ERBB2 Loss in breast carcinoma [5].
Malignant Solid Tumor +
ERBB2 is altered in 5.44% of malignant solid tumor patients with ERBB2 Loss present in 0.03% of all malignant solid tumor patients [4].
ERBB2 Loss is an inclusion criterion in 132 clinical trials for malignant solid tumor, of which 93 are open and 39 are closed. Of the trials that contain ERBB2 Loss and malignant solid tumor as inclusion criteria, 1 is early phase 1 (1 open), 88 are phase 1 (58 open), 37 are phase 1/phase 2 (29 open), and 6 are phase 2 (5 open) [5].
Non-Small Cell Lung Carcinoma +
ERBB2 is altered in 3.97% of non-small cell lung carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 98 clinical trials for non-small cell lung carcinoma, of which 63 are open and 35 are closed. Of the trials that contain ERBB2 Loss and non-small cell lung carcinoma as inclusion criteria, 55 are phase 1 (30 open), 28 are phase 1/phase 2 (20 open), and 15 are phase 2 (13 open) [5].
Ovarian Carcinoma +
ERBB2 is altered in 3.28% of ovarian carcinoma patients with ERBB2 Loss present in 0.25% of all ovarian carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 83 clinical trials for ovarian carcinoma, of which 54 are open and 29 are closed. Of the trials that contain ERBB2 Loss and ovarian carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 49 are phase 1 (25 open), 24 are phase 1/phase 2 (19 open), and 9 are phase 2 (9 open) [5].
Colorectal Carcinoma +
ERBB2 is altered in 4.69% of colorectal carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 58 clinical trials for colorectal carcinoma, of which 41 are open and 17 are closed. Of the trials that contain ERBB2 Loss and colorectal carcinoma as inclusion criteria, 39 are phase 1 (27 open), 15 are phase 1/phase 2 (11 open), and 4 are phase 2 (3 open) [5].
Invasive Breast Carcinoma +
ERBB2 is altered in 13.88% of invasive breast carcinoma patients with ERBB2 Loss present in 0.03% of all invasive breast carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 51 clinical trials for invasive breast carcinoma, of which 50 are open and 1 is closed. Of the trials that contain ERBB2 Loss and invasive breast carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 6 are phase 1 (6 open), 2 are phase 1/phase 2 (2 open), 35 are phase 2 (34 open), 1 is phase 2/phase 3 (1 open), 4 are phase 3 (4 open), and 2 are no phase specified (2 open) [5].
Head And Neck Squamous Cell Carcinoma +
ERBB2 is altered in 2.81% of head and neck squamous cell carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 45 clinical trials for head and neck squamous cell carcinoma, of which 31 are open and 14 are closed. Of the trials that contain ERBB2 Loss and head and neck squamous cell carcinoma as inclusion criteria, 27 are phase 1 (15 open), 16 are phase 1/phase 2 (14 open), and 2 are phase 2 (2 open) [5].
Breast Adenocarcinoma +
ERBB2 is altered in 13.55% of breast adenocarcinoma patients with ERBB2 Loss present in 0.01% of all breast adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 44 clinical trials for breast adenocarcinoma, of which 41 are open and 3 are closed. Of the trials that contain ERBB2 Loss and breast adenocarcinoma as inclusion criteria, 1 is early phase 1 (1 open), 11 are phase 1 (11 open), 5 are phase 1/phase 2 (4 open), 15 are phase 2 (14 open), 1 is phase 2/phase 3 (1 open), 9 are phase 3 (8 open), and 2 are no phase specified (2 open) [5].
Gastric Carcinoma +
ERBB2 is altered in 10.1% of gastric carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 43 clinical trials for gastric carcinoma, of which 25 are open and 18 are closed. Of the trials that contain ERBB2 Loss and gastric carcinoma as inclusion criteria, 21 are phase 1 (10 open), 13 are phase 1/phase 2 (9 open), 7 are phase 2 (5 open), and 2 are phase 3 (1 open) [5].
Melanoma +
ERBB2 is altered in 3.29% of melanoma patients with ERBB2 Loss present in 0.05% of all melanoma patients [4].
ERBB2 Loss is an inclusion criterion in 41 clinical trials for melanoma, of which 25 are open and 16 are closed. Of the trials that contain ERBB2 Loss and melanoma as inclusion criteria, 1 is early phase 1 (0 open), 25 are phase 1 (15 open), 7 are phase 1/phase 2 (4 open), and 8 are phase 2 (6 open) [5].
Adenocarcinoma Of The Gastroesophageal Junction +
ERBB2 is altered in 19.62% of adenocarcinoma of the gastroesophageal junction patients [4].
ERBB2 Loss is an inclusion criterion in 37 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 25 are open and 12 are closed. Of the trials that contain ERBB2 Loss and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 15 are phase 1 (9 open), 7 are phase 1/phase 2 (5 open), 6 are phase 2 (5 open), 1 is phase 2/phase 3 (1 open), 7 are phase 3 (5 open), and 1 is no phase specified (0 open) [5].
Fallopian Tube Carcinoma +
ERBB2 Loss is an inclusion criterion in 34 clinical trials for fallopian tube carcinoma, of which 22 are open and 12 are closed. Of the trials that contain ERBB2 Loss and fallopian tube carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 22 are phase 1 (11 open), 7 are phase 1/phase 2 (6 open), 3 are phase 2 (3 open), and 1 is phase 4 (1 open) [5].
Pancreatic Carcinoma +
ERBB2 is altered in 2.14% of pancreatic carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 34 clinical trials for pancreatic carcinoma, of which 25 are open and 9 are closed. Of the trials that contain ERBB2 Loss and pancreatic carcinoma as inclusion criteria, 21 are phase 1 (14 open), 11 are phase 1/phase 2 (9 open), and 2 are phase 2 (2 open) [5].
Primary Peritoneal Carcinoma +
ERBB2 is altered in 8.7% of primary peritoneal carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 32 clinical trials for primary peritoneal carcinoma, of which 20 are open and 12 are closed. Of the trials that contain ERBB2 Loss and primary peritoneal carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 20 are phase 1 (9 open), 7 are phase 1/phase 2 (6 open), 3 are phase 2 (3 open), and 1 is phase 4 (1 open) [5].
Renal Cell Carcinoma +
ERBB2 is altered in 1.11% of renal cell carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 32 clinical trials for renal cell carcinoma, of which 20 are open and 12 are closed. Of the trials that contain ERBB2 Loss and renal cell carcinoma as inclusion criteria, 19 are phase 1 (9 open), 8 are phase 1/phase 2 (7 open), and 5 are phase 2 (4 open) [5].
Urothelial Carcinoma +
ERBB2 is altered in 14.87% of urothelial carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 32 clinical trials for urothelial carcinoma, of which 22 are open and 10 are closed. Of the trials that contain ERBB2 Loss and urothelial carcinoma as inclusion criteria, 18 are phase 1 (10 open), 11 are phase 1/phase 2 (9 open), and 3 are phase 2 (3 open) [5].
Prostate Carcinoma +
ERBB2 is altered in 1.14% of prostate carcinoma patients with ERBB2 Loss present in 0.03% of all prostate carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 31 clinical trials for prostate carcinoma, of which 21 are open and 10 are closed. Of the trials that contain ERBB2 Loss and prostate carcinoma as inclusion criteria, 21 are phase 1 (12 open), 7 are phase 1/phase 2 (6 open), and 3 are phase 2 (3 open) [5].
Small Cell Lung Carcinoma +
ERBB2 is altered in 2.64% of small cell lung carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 31 clinical trials for small cell lung carcinoma, of which 23 are open and 8 are closed. Of the trials that contain ERBB2 Loss and small cell lung carcinoma as inclusion criteria, 15 are phase 1 (10 open), 12 are phase 1/phase 2 (9 open), and 4 are phase 2 (4 open) [5].
Gastric Adenocarcinoma +
ERBB2 is altered in 10.08% of gastric adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 30 clinical trials for gastric adenocarcinoma, of which 23 are open and 7 are closed. Of the trials that contain ERBB2 Loss and gastric adenocarcinoma as inclusion criteria, 9 are phase 1 (6 open), 7 are phase 1/phase 2 (6 open), 6 are phase 2 (5 open), 1 is phase 2/phase 3 (1 open), 6 are phase 3 (5 open), and 1 is no phase specified (0 open) [5].
Endometrial Carcinoma +
ERBB2 is altered in 8.93% of endometrial carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 27 clinical trials for endometrial carcinoma, of which 22 are open and 5 are closed. Of the trials that contain ERBB2 Loss and endometrial carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 15 are phase 1 (12 open), 10 are phase 1/phase 2 (8 open), and 1 is phase 2 (1 open) [5].
Esophageal Carcinoma +
ERBB2 is altered in 16.67% of esophageal carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 24 clinical trials for esophageal carcinoma, of which 14 are open and 10 are closed. Of the trials that contain ERBB2 Loss and esophageal carcinoma as inclusion criteria, 8 are phase 1 (3 open), 10 are phase 1/phase 2 (8 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [5].
Bladder Carcinoma +
ERBB2 is altered in 14.96% of bladder carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 21 clinical trials for bladder carcinoma, of which 12 are open and 9 are closed. Of the trials that contain ERBB2 Loss and bladder carcinoma as inclusion criteria, 13 are phase 1 (5 open), 5 are phase 1/phase 2 (4 open), and 3 are phase 2 (3 open) [5].
Hepatocellular Carcinoma +
ERBB2 is altered in 0.23% of hepatocellular carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 20 clinical trials for hepatocellular carcinoma, of which 16 are open and 4 are closed. Of the trials that contain ERBB2 Loss and hepatocellular carcinoma as inclusion criteria, 13 are phase 1 (10 open) and 7 are phase 1/phase 2 (6 open) [5].
Cervical Carcinoma +
ERBB2 is altered in 9.09% of cervical carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 19 clinical trials for cervical carcinoma, of which 15 are open and 4 are closed. Of the trials that contain ERBB2 Loss and cervical carcinoma as inclusion criteria, 13 are phase 1 (10 open) and 6 are phase 1/phase 2 (5 open) [5].
Pancreatic Adenocarcinoma +
ERBB2 is altered in 2.15% of pancreatic adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 14 clinical trials for pancreatic adenocarcinoma, of which 9 are open and 5 are closed. Of the trials that contain ERBB2 Loss and pancreatic adenocarcinoma as inclusion criteria, 7 are phase 1 (5 open), 6 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [5].
Soft Tissue Sarcoma +
ERBB2 is altered in 0.91% of soft tissue sarcoma patients with ERBB2 Loss present in 0.05% of all soft tissue sarcoma patients [4].
ERBB2 Loss is an inclusion criterion in 13 clinical trials for soft tissue sarcoma, of which 8 are open and 5 are closed. Of the trials that contain ERBB2 Loss and soft tissue sarcoma as inclusion criteria, 8 are phase 1 (3 open) and 5 are phase 1/phase 2 (5 open) [5].
Head And Neck Carcinoma +
ERBB2 is altered in 4.04% of head and neck carcinoma patients with ERBB2 Loss present in 0.06% of all head and neck carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 12 clinical trials for head and neck carcinoma, of which 8 are open and 4 are closed. Of the trials that contain ERBB2 Loss and head and neck carcinoma as inclusion criteria, 9 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].
Lymphoma +
ERBB2 is altered in 1.34% of lymphoma patients with ERBB2 Loss present in 0.05% of all lymphoma patients [4].
ERBB2 Loss is an inclusion criterion in 11 clinical trials for lymphoma, of which 5 are open and 6 are closed. Of the trials that contain ERBB2 Loss and lymphoma as inclusion criteria, 8 are phase 1 (4 open) and 3 are phase 1/phase 2 (1 open) [5].
Squamous Cell Lung Carcinoma +
ERBB2 is altered in 2.04% of squamous cell lung carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 11 clinical trials for squamous cell lung carcinoma, of which 9 are open and 2 are closed. Of the trials that contain ERBB2 Loss and squamous cell lung carcinoma as inclusion criteria, 7 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [5].
Breast Invasive Ductal Carcinoma +
ERBB2 is altered in 14.14% of breast invasive ductal carcinoma patients with ERBB2 Loss present in 0.02% of all breast invasive ductal carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 8 clinical trials for breast invasive ductal carcinoma, of which 7 are open and 1 is closed. Of the trials that contain ERBB2 Loss and breast invasive ductal carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 1 is phase 2 (1 open), 2 are phase 3 (2 open), and 2 are no phase specified (1 open) [5].
Mesothelioma +
ERBB2 Loss is an inclusion criterion in 8 clinical trials for mesothelioma, of which 5 are open and 3 are closed. Of the trials that contain ERBB2 Loss and mesothelioma as inclusion criteria, 8 are phase 1 (5 open) [5].
Pancreatic Ductal Adenocarcinoma +
ERBB2 Loss is an inclusion criterion in 8 clinical trials for pancreatic ductal adenocarcinoma, of which 4 are open and 4 are closed. Of the trials that contain ERBB2 Loss and pancreatic ductal adenocarcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (0 open), and 1 is phase 2 (0 open) [5].
Glioblastoma +
ERBB2 is altered in 1.84% of glioblastoma patients with ERBB2 Loss present in 0.1% of all glioblastoma patients [4].
ERBB2 Loss is an inclusion criterion in 7 clinical trials for glioblastoma, of which 3 are open and 4 are closed. Of the trials that contain ERBB2 Loss and glioblastoma as inclusion criteria, 4 are phase 1 (2 open), 2 are phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].
Prostate Adenocarcinoma +
ERBB2 is altered in 1.09% of prostate adenocarcinoma patients with ERBB2 Loss present in 0.03% of all prostate adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 7 clinical trials for prostate adenocarcinoma, of which 6 are open and 1 is closed. Of the trials that contain ERBB2 Loss and prostate adenocarcinoma as inclusion criteria, 3 are phase 1 (3 open) and 4 are phase 1/phase 2 (3 open) [5].
Ductal Carcinoma In Situ +
ERBB2 is altered in 3.08% of ductal carcinoma in situ patients [4].
ERBB2 Loss is an inclusion criterion in 7 clinical trials for ductal carcinoma in situ, of which 6 are open and 1 is closed. Of the trials that contain ERBB2 Loss and ductal carcinoma in situ as inclusion criteria, 5 are phase 2 (4 open) and 2 are no phase specified (2 open) [5].
Sarcoma +
ERBB2 is altered in 1.0% of sarcoma patients with ERBB2 Loss present in 0.08% of all sarcoma patients [4].
ERBB2 Loss is an inclusion criterion in 6 clinical trials for sarcoma, of which 3 are open and 3 are closed. Of the trials that contain ERBB2 Loss and sarcoma as inclusion criteria, 3 are phase 1 (1 open) and 3 are phase 1/phase 2 (2 open) [5].
Colorectal Adenocarcinoma +
ERBB2 is altered in 4.69% of colorectal adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 6 clinical trials for colorectal adenocarcinoma, of which 5 are open and 1 is closed. Of the trials that contain ERBB2 Loss and colorectal adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) and 4 are phase 1/phase 2 (3 open) [5].
Esophageal Adenocarcinoma +
ERBB2 is altered in 19.0% of esophageal adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 6 clinical trials for esophageal adenocarcinoma, of which 6 are open and 0 are closed. Of the trials that contain ERBB2 Loss and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [5].
Inflammatory Breast Carcinoma +
ERBB2 is altered in 21.43% of inflammatory breast carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 6 clinical trials for inflammatory breast carcinoma, of which 6 are open and 0 are closed. Of the trials that contain ERBB2 Loss and inflammatory breast carcinoma as inclusion criteria, 6 are phase 2 (6 open) [5].
Nasopharyngeal Carcinoma +
ERBB2 Loss is an inclusion criterion in 6 clinical trials for nasopharyngeal carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ERBB2 Loss and nasopharyngeal carcinoma as inclusion criteria, 5 are phase 1 (4 open) and 1 is phase 1/phase 2 (1 open) [5].
High Grade Ovarian Serous Adenocarcinoma +
ERBB2 is altered in 2.91% of high grade ovarian serous adenocarcinoma patients with ERBB2 Loss present in 0.35% of all high grade ovarian serous adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 5 clinical trials for high grade ovarian serous adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain ERBB2 Loss and high grade ovarian serous adenocarcinoma as inclusion criteria, 4 are phase 1 (3 open) and 1 is phase 1/phase 2 (1 open) [5].
Cancer +
ERBB2 is altered in 5.14% of cancer patients with ERBB2 Loss present in 0.03% of all cancer patients [4].
ERBB2 Loss is an inclusion criterion in 5 clinical trials for cancer, of which 2 are open and 3 are closed. Of the trials that contain ERBB2 Loss and cancer as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [5].
Acute Myeloid Leukemia +
ERBB2 is altered in 0.45% of acute myeloid leukemia patients [4].
ERBB2 Loss is an inclusion criterion in 5 clinical trials for acute myeloid leukemia, of which 4 are open and 1 is closed. Of the trials that contain ERBB2 Loss and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 1/phase 2 (2 open) [5].
Cholangiocarcinoma +
ERBB2 is altered in 4.07% of cholangiocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 5 clinical trials for cholangiocarcinoma, of which 3 are open and 2 are closed. Of the trials that contain ERBB2 Loss and cholangiocarcinoma as inclusion criteria, 4 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [5].
Esophagogastric Carcinoma +
ERBB2 is altered in 14.54% of esophagogastric carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 5 clinical trials for esophagogastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain ERBB2 Loss and esophagogastric carcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open) [5].
Merkel Cell Carcinoma +
ERBB2 is altered in 0.85% of Merkel cell carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 5 clinical trials for Merkel cell carcinoma, of which 4 are open and 1 is closed. Of the trials that contain ERBB2 Loss and Merkel cell carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 3 are phase 1/phase 2 (3 open) [5].
Peritoneal Mesothelioma +
ERBB2 Loss is an inclusion criterion in 5 clinical trials for peritoneal mesothelioma, of which 2 are open and 3 are closed. Of the trials that contain ERBB2 Loss and peritoneal mesothelioma as inclusion criteria, 4 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].
Malignant Ovarian Epithelial Tumor +
ERBB2 is altered in 3.41% of malignant ovarian epithelial tumor patients with ERBB2 Loss present in 0.23% of all malignant ovarian epithelial tumor patients [4].
ERBB2 Loss is an inclusion criterion in 4 clinical trials for malignant ovarian epithelial tumor, of which 4 are open and 0 are closed. Of the trials that contain ERBB2 Loss and malignant ovarian epithelial tumor as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 4 (1 open) [5].
Non-Hodgkin Lymphoma +
ERBB2 is altered in 1.49% of non-hodgkin lymphoma patients with ERBB2 Loss present in 0.07% of all non-hodgkin lymphoma patients [4].
ERBB2 Loss is an inclusion criterion in 4 clinical trials for non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain ERBB2 Loss and non-hodgkin lymphoma as inclusion criteria, 4 are phase 1 (4 open) [5].
Chronic Lymphocytic Leukemia +
ERBB2 Loss is an inclusion criterion in 4 clinical trials for chronic lymphocytic leukemia, of which 2 are open and 2 are closed. Of the trials that contain ERBB2 Loss and chronic lymphocytic leukemia as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [5].
Clear Cell Renal Cell Carcinoma +
ERBB2 is altered in 1.28% of clear cell renal cell carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 4 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 2 are closed. Of the trials that contain ERBB2 Loss and clear cell renal cell carcinoma as inclusion criteria, 3 are phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Diffuse Large B-Cell Lymphoma +
ERBB2 is altered in 2.83% of diffuse large B-cell lymphoma patients [4].
ERBB2 Loss is an inclusion criterion in 4 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 2 are closed. Of the trials that contain ERBB2 Loss and diffuse large B-cell lymphoma as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].
Multiple Myeloma +
ERBB2 is altered in 0.83% of multiple myeloma patients [4].
ERBB2 Loss is an inclusion criterion in 4 clinical trials for multiple myeloma, of which 3 are open and 1 is closed. Of the trials that contain ERBB2 Loss and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 1/phase 2 (2 open) [5].
Carcinoma +
ERBB2 is altered in 6.45% of carcinoma patients with ERBB2 Loss present in 0.03% of all carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 3 clinical trials for carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 Loss and carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [5].
Breast Invasive Lobular Carcinoma +
ERBB2 is altered in 12.05% of breast invasive lobular carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 3 clinical trials for breast invasive lobular carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 Loss and breast invasive lobular carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].
Breast Lobular Carcinoma In Situ +
ERBB2 Loss is an inclusion criterion in 3 clinical trials for breast lobular carcinoma in situ, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 Loss and breast lobular carcinoma in situ as inclusion criteria, 2 are phase 2 (2 open) and 1 is no phase specified (1 open) [5].
Colon Carcinoma +
ERBB2 is altered in 5.2% of colon carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 3 clinical trials for colon carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ERBB2 Loss and colon carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Cutaneous Melanoma +
ERBB2 is altered in 4.05% of cutaneous melanoma patients [4].
ERBB2 Loss is an inclusion criterion in 3 clinical trials for cutaneous melanoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 Loss and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].
Esophageal Squamous Cell Carcinoma +
ERBB2 is altered in 4.73% of esophageal squamous cell carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 3 clinical trials for esophageal squamous cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 Loss and esophageal squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [5].
High Grade Fallopian Tube Serous Adenocarcinoma +
ERBB2 Loss is an inclusion criterion in 3 clinical trials for high grade fallopian tube serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain ERBB2 Loss and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].
Lung Adenocarcinoma +
ERBB2 is altered in 4.32% of lung adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 3 clinical trials for lung adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain ERBB2 Loss and lung adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].
Malignant Pleural Mesothelioma +
ERBB2 Loss is an inclusion criterion in 3 clinical trials for malignant pleural mesothelioma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 Loss and malignant pleural mesothelioma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [5].
Mantle Cell Lymphoma +
ERBB2 is altered in 0.56% of mantle cell lymphoma patients [4].
ERBB2 Loss is an inclusion criterion in 3 clinical trials for mantle cell lymphoma, of which 2 are open and 1 is closed. Of the trials that contain ERBB2 Loss and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [5].
Pleural Mesothelioma +
ERBB2 Loss is an inclusion criterion in 3 clinical trials for pleural mesothelioma, of which 0 are open and 3 are closed. Of the trials that contain ERBB2 Loss and pleural mesothelioma as inclusion criteria, 3 are phase 1 (0 open) [5].
Skin Squamous Cell Carcinoma +
ERBB2 is altered in 5.83% of skin squamous cell carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 3 clinical trials for skin squamous cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 Loss and skin squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [5].
Neuroendocrine Carcinoma +
ERBB2 is altered in 2.98% of neuroendocrine carcinoma patients with ERBB2 Loss present in 0.17% of all neuroendocrine carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for neuroendocrine carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 Loss and neuroendocrine carcinoma as inclusion criteria, 2 are phase 1 (1 open) [5].
Hematopoietic And Lymphoid Malignancy +
ERBB2 is altered in 0.87% of hematopoietic and lymphoid malignancy patients with ERBB2 Loss present in 0.02% of all hematopoietic and lymphoid malignancy patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for hematopoietic and lymphoid malignancy, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].
Acute Lymphoblastic Leukemia +
ERBB2 Loss is an inclusion criterion in 2 clinical trials for acute lymphoblastic leukemia, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 Loss and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].
Adenoid Cystic Carcinoma +
ERBB2 is altered in 1.32% of adenoid cystic carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for adenoid cystic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 Loss and adenoid cystic carcinoma as inclusion criteria, 2 are phase 1 (1 open) [5].
Anal Canal Squamous Cell Carcinoma +
ERBB2 Loss is an inclusion criterion in 2 clinical trials for anal canal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and anal canal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].
B-Cell Non-Hodgkin Lymphoma +
ERBB2 is altered in 1.62% of B-cell non-hodgkin lymphoma patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for B-cell non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and B-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].
Biliary Tract Carcinoma +
ERBB2 is altered in 5.41% of biliary tract carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for biliary tract carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and biliary tract carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].
Cervical Squamous Cell Carcinoma +
ERBB2 is altered in 6.22% of cervical squamous cell carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for cervical squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and cervical squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].
Classical Hodgkin Lymphoma +
ERBB2 Loss is an inclusion criterion in 2 clinical trials for classical hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and classical hodgkin lymphoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].
Endometrial Endometrioid Adenocarcinoma +
ERBB2 is altered in 7.66% of endometrial endometrioid adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for endometrial endometrioid adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and endometrial endometrioid adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].
Fallopian Tube Endometrioid Adenocarcinoma +
ERBB2 Loss is an inclusion criterion in 2 clinical trials for fallopian tube endometrioid adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 Loss and fallopian tube endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].
Gallbladder Carcinoma +
ERBB2 is altered in 10.45% of gallbladder carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for gallbladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and gallbladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Gastrointestinal Stromal Tumor +
ERBB2 is altered in 0.54% of gastrointestinal stromal tumor patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 Loss and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].
Intrahepatic Cholangiocarcinoma +
ERBB2 is altered in 2.89% of intrahepatic cholangiocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for intrahepatic cholangiocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Kidney Carcinoma +
ERBB2 is altered in 1.14% of kidney carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for kidney carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and kidney carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].
Lobular Breast Carcinoma +
ERBB2 is altered in 11.97% of lobular breast carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for lobular breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and lobular breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].
Malignant Ovarian Clear Cell Tumor +
ERBB2 is altered in 5.45% of malignant ovarian clear cell tumor patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for malignant ovarian clear cell tumor, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and malignant ovarian clear cell tumor as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].
Malignant Uterine Neoplasm +
ERBB2 is altered in 8.03% of malignant uterine neoplasm patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for malignant uterine neoplasm, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and malignant uterine neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].
Mixed Lobular And Ductal Breast Carcinoma +
ERBB2 is altered in 9.77% of mixed lobular and ductal breast carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for mixed lobular and ductal breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and mixed lobular and ductal breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].
Myelodysplastic Syndromes +
ERBB2 is altered in 0.41% of myelodysplastic syndromes patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 Loss and myelodysplastic syndromes as inclusion criteria, 2 are phase 1/phase 2 (1 open) [5].
Non-Squamous Non-Small Cell Lung Carcinoma +
ERBB2 is altered in 4.28% of non-squamous non-small cell lung carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for non-squamous non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Primary Peritoneal Serous Adenocarcinoma +
ERBB2 is altered in 8.7% of primary peritoneal serous adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for primary peritoneal serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and primary peritoneal serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].
Small Intestinal Adenocarcinoma +
ERBB2 is altered in 12.73% of small intestinal adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for small intestinal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 Loss and small intestinal adenocarcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [5].
Thyroid Gland Carcinoma +
ERBB2 is altered in 0.8% of thyroid gland carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and thyroid gland carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].
Synovial Sarcoma +
ERBB2 is altered in 1.59% of synovial sarcoma patients with ERBB2 Loss present in 0.85% of all synovial sarcoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for synovial sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and synovial sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Anal Squamous Cell Carcinoma +
ERBB2 is altered in 4.12% of anal squamous cell carcinoma patients with ERBB2 Loss present in 0.68% of all anal squamous cell carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for anal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and anal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Anal Carcinoma +
ERBB2 is altered in 4.46% of anal carcinoma patients with ERBB2 Loss present in 0.66% of all anal carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and anal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Pancreatic Neuroendocrine Neoplasm +
ERBB2 is altered in 2.02% of pancreatic neuroendocrine neoplasm patients with ERBB2 Loss present in 0.3% of all pancreatic neuroendocrine neoplasm patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for pancreatic neuroendocrine neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and pancreatic neuroendocrine neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].
Ovarian Epithelial Tumor +
ERBB2 is altered in 3.48% of ovarian epithelial tumor patients with ERBB2 Loss present in 0.22% of all ovarian epithelial tumor patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for ovarian epithelial tumor, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].
T-Cell And NK-Cell Neoplasm +
ERBB2 is altered in 0.62% of T-cell and NK-cell neoplasm patients with ERBB2 Loss present in 0.22% of all T-cell and NK-cell neoplasm patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [5].
Salivary Gland Carcinoma +
ERBB2 is altered in 6.96% of salivary gland carcinoma patients with ERBB2 Loss present in 0.21% of all salivary gland carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for salivary gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and salivary gland carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Malignant Glioma +
ERBB2 is altered in 1.71% of malignant glioma patients with ERBB2 Loss present in 0.08% of all malignant glioma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for malignant glioma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and malignant glioma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].
Central Nervous System Neoplasm +
ERBB2 is altered in 1.37% of central nervous system neoplasm patients with ERBB2 Loss present in 0.07% of all central nervous system neoplasm patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].
Malignant Digestive System Neoplasm +
ERBB2 is altered in 5.64% of malignant digestive system neoplasm patients with ERBB2 Loss present in 0.01% of all malignant digestive system neoplasm patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for malignant digestive system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and malignant digestive system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].
Anaplastic Astrocytoma +
ERBB2 is altered in 1.51% of anaplastic astrocytoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [5].
Benign Breast Neoplasm +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for benign breast neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and benign breast neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].
Bilateral Breast Carcinoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for bilateral breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and bilateral breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Bladder Urothelial Carcinoma +
ERBB2 is altered in 15.57% of bladder urothelial carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and bladder urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Cervical Carcinosarcoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for cervical carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and cervical carcinosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Chordoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for chordoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and chordoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Diffuse Intrinsic Pontine Glioma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for diffuse intrinsic pontine glioma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].
Endometrial Adenocarcinoma +
ERBB2 is altered in 9.01% of endometrial adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for endometrial adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and endometrial adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].
Endometrial Mixed Adenocarcinoma +
ERBB2 is altered in 15.09% of endometrial mixed adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for endometrial mixed adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and endometrial mixed adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Endometrial Serous Adenocarcinoma +
ERBB2 is altered in 11.17% of endometrial serous adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for endometrial serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and endometrial serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Ependymoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for ependymoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and ependymoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].
Extrahepatic Cholangiocarcinoma +
ERBB2 is altered in 8.97% of extrahepatic cholangiocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for extrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and extrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Fallopian Tube Clear Cell Adenocarcinoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for fallopian tube clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and fallopian tube clear cell adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Gastric Diffuse Adenocarcinoma +
ERBB2 is altered in 4.72% of gastric diffuse adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for gastric diffuse adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and gastric diffuse adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Hypopharyngeal Carcinoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for hypopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and hypopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Hypopharyngeal Squamous Cell Carcinoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for hypopharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and hypopharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Kaposi Sarcoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for Kaposi sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and Kaposi sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Laryngeal Squamous Cell Carcinoma +
ERBB2 is altered in 2.35% of laryngeal squamous cell carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for laryngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and laryngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Malignant Mixed Mesodermal (Mullerian) Tumor +
ERBB2 is altered in 5.9% of malignant mixed mesodermal (mullerian) tumor patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for malignant mixed mesodermal (mullerian) tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and malignant mixed mesodermal (mullerian) tumor as inclusion criteria, 1 is early phase 1 (1 open) [5].
Malignant Ovarian Endometrioid Tumor +
ERBB2 is altered in 5.54% of malignant ovarian endometrioid tumor patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (1 open) [5].
Malignant Thyroid Gland Neoplasm +
ERBB2 is altered in 0.8% of malignant thyroid gland neoplasm patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for malignant thyroid gland neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and malignant thyroid gland neoplasm as inclusion criteria, 1 is phase 1 (0 open) [5].
Medullary Breast Carcinoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for medullary breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and medullary breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
NUT Midline Carcinoma Of The Head And Neck +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for NUT midline carcinoma of the head and neck, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and NUT midline carcinoma of the head and neck as inclusion criteria, 1 is phase 1 (0 open) [5].
Oropharyngeal Carcinoma +
ERBB2 is altered in 3.6% of oropharyngeal carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Oropharyngeal Squamous Cell Carcinoma +
ERBB2 is altered in 3.6% of oropharyngeal squamous cell carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Ovarian Endometrioid Adenocarcinoma +
ERBB2 is altered in 8.21% of ovarian endometrioid adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for ovarian endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and ovarian endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].
Ovarian Endometrioid Tumor +
ERBB2 is altered in 5.51% of ovarian endometrioid tumor patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for ovarian endometrioid tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and ovarian endometrioid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Papillary Renal Cell Carcinoma +
ERBB2 is altered in 0.68% of papillary renal cell carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].
Penile Carcinoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and penile carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Primary Cutaneous T Cell Non-Hodgkin Lymphoma +
ERBB2 is altered in 1.01% of primary cutaneous T cell non-hodgkin lymphoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for primary cutaneous T cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and primary cutaneous T cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Primary Mediastinal B-Cell Lymphoma +
ERBB2 is altered in 5.56% of primary mediastinal B-cell lymphoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for primary mediastinal B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and primary mediastinal B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Primary Peritoneal Carcinosarcoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for primary peritoneal carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and primary peritoneal carcinosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Primitive Neuroectodermal Tumor +
ERBB2 is altered in 2.37% of primitive neuroectodermal tumor patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for primitive neuroectodermal tumor, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and primitive neuroectodermal tumor as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].
Prostate Undifferentiated Carcinoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for prostate undifferentiated carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and prostate undifferentiated carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].
Renal Pelvis And Ureter Carcinoma +
ERBB2 is altered in 11.89% of renal pelvis and ureter carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for renal pelvis and ureter carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and renal pelvis and ureter carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Squamous Cell Carcinoma Of The Penis +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for squamous cell carcinoma of the penis, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and squamous cell carcinoma of the penis as inclusion criteria, 1 is phase 1 (1 open) [5].
Tenosynovial Giant Cell Tumor +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for tenosynovial giant cell tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and tenosynovial giant cell tumor as inclusion criteria, 1 is phase 2 (1 open) [5].
Tenosynovial Giant Cell Tumor, Diffuse Type +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for tenosynovial giant cell tumor, diffuse type, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and tenosynovial giant cell tumor, diffuse type as inclusion criteria, 1 is phase 2 (1 open) [5].
Thyroid Gland Follicular Carcinoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for thyroid gland follicular carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and thyroid gland follicular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma +
ERBB2 is altered in 2.11% of thyroid gland undifferentiated (anaplastic) carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Transitional Cell Carcinoma +
ERBB2 is altered in 14.87% of transitional cell carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for transitional cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and transitional cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Ureter Urothelial Carcinoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for ureter urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and ureter urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Uterine Corpus Carcinosarcoma +
ERBB2 is altered in 7.17% of uterine corpus carcinosarcoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for uterine corpus carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and uterine corpus carcinosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Uveal Melanoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and uveal melanoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Vulvar Carcinoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and vulvar carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Well-Differentiated Thyroid Gland Carcinoma +
ERBB2 is altered in 0.77% of well-differentiated thyroid gland carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for well-differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and well-differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
